Arnaud Lallouette/LinkedIn
Sep 3, 2025, 15:15
Arnaud Lallouette: Servier and IDEAYA Partner to Bring a Promising Uveal Melanoma Treatment
Arnaud Lallouette, Executive Vice President Global Medical and Patient Affairs at Servier, shared a post on LinkedIn:
“At Servier, our mission is clear: to deliver transformative therapies to patients with significant unmet needs.
Today, we are taking another important step forward through a strategic partnership with IDEAYA Biosciences.
This licensing agreement aims to address an important medical need for patients living with a rare and aggressive eye cancer with limited treatment options remain limited.
We are ready to leverage our global oncology network and expertise with a simple ambition: to truly change the future for patients.”
More Posts Featuring Arnaud Lallouette at OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 3, 2025, 15:15
Sep 3, 2025, 14:57
Sep 3, 2025, 14:37
Sep 3, 2025, 14:20
Sep 3, 2025, 13:54
Sep 3, 2025, 13:18
Sep 3, 2025, 13:14
Sep 3, 2025, 13:10